Related by context. Frequent words. (Click for all words.) 63 Medication Delivery 60 PTOI 60 ADT Worldwide 57 Engineered Products segment 56 Fluid Handling 55 Protective Packaging 55 Q2 FY# [001] 55 Flat Rolled Products 55 Electrical Equipment Appliances 54 MedSurg 54 Performance Plastics 54 WhiteWave Morningstar 54 Segment EBIT 54 BD Diagnostics 54 BioPharmaceuticals 53 Retail Leathercraft 53 3Q FY# 52 Non GAAP adjusted EBITDA 52 MDS Analytical Technologies 52 Angio Seal TM 52 excluding divestments 52 Immunoassay 52 Surgical Instruments 52 Q#/# EUR [001] 52 Inland Barge Group 52 Industrial Specialties 52 FQ = fiscal 51 IVIS 51 orthopedic reconstructive 51 reagent kits 51 GeneChip R 51 Normalized EBITDA 50 intersegment sales 50 Flat Panel Displays 50 Proprietary Products 50 Lenovo AsiaInfo 50 Engineered Solutions 50 immunodiagnostic 50 OPERATING EXPENSES Cost 50 Clinical Therapies 50 biosurgery 50 BioMarin Genzyme LLC 50 Q3 FY# [001] 50 Flow Cytometry 50 Performance Chemicals 50 Reconciling Items 50 DNA Sequencing 50 - RevenBrz 50 Teleflex Incorporated 49 Engineered Films 49 Clinical Diagnostics 49 Analytical Technologies 49 GSPU 49 Specialty Plastics 49 Operating Expenses Operating 49 COST OF GOODS SOLD 49 intersegment revenues 49 chemistry analyzers 49 Underlying EBIT 49 CooperSurgical 49 Dade Behring Holdings 48 LabChip 48 NET REVENUES 48 GROSS MARGIN 48 Segment wise 48 Tubular Services 48 dental reconstructive 48 Omnicare pharmacy 48 TriPath 48 Xtria 48 Microvolt T Wave Alternans 48 Vacation Interval sales 48 Versa subcompact 48 Administrative Expense 48 Diagnostics 48 POCT 48 Fuel Specialties 48 orthobiologic 48 - Operating [025] 48 2Q FY# [001] 48 - OpeDHQ 48 Pro Forma Adjusted EBITDA 48 GeneChip 48 Affymetrix GeneChip R 48 Seamap 48 Noninterest 48 Intersegment Eliminations 48 Non Regulated 47 Biosurgery 47 FORE SIGHT 47 Perfusion 47 Alverix 47 Specialty Printing 47 intercompany eliminations 47 Bell Wireline 47 lubricant additives 47 Digital Radiography 47 SangStat 47 Decorative Products 47 Pro Forma Net 47 Q2 FY'#